A patient shows up with pinpoint pupils, slowed breathing, and every sign of opioid intoxication, but the 12-panel cup comes back clean across OPI, OXY, and FYL. That gap is not a testing failure. It is tianeptine, a substance sold openly at gas stations and smoke shops that behaves like an opioid in the body but is invisible to the immunoassay panels most programs run every day.
Tianeptine is an antidepressant approved for prescription use in parts of Europe, Asia, and Latin America under brand names like Coaxil and Stablon, at doses around 12.5 milligrams three times a day. It has never been approved by the FDA for any use in the United States. What is sold here under names like Zaza, Tianaa, Neptune's Fix, Pegasus, and TD Red is an unregulated product, often marketed as a nootropic, a mood enhancer, or a dietary supplement, with no requirement that the label reflect what is actually inside the package. The FDA has warned consumers directly not to purchase or use any tianeptine product, citing reports of seizures, loss of consciousness, and death.
What tianeptine actually is
Chemically, tianeptine is a tricyclic compound, but its behavior in the body has little in common with a typical antidepressant. Research using animal models has shown that tianeptine and its active metabolite act as agonists at the mu-opioid receptor, the same receptor site targeted by morphine, oxycodone, and fentanyl. A study published through the National Institutes of Health found that tianeptine signaling in the brain shares functional properties with DAMGO, a standard reference compound for opioid receptor activity, and that repeated use produces tolerance in the same pattern seen with conventional opioids. That mechanism explains why heavy users describe euphoria, why cessation produces an opioid-like withdrawal syndrome, and why naloxone has reversed toxicity in documented overdose cases. Details on the receptor mechanism are available through the National Institutes of Health's PubMed Central archive.
Federal reviewers who examined the pharmacology reached the same conclusion. In a proposed rule to place tianeptine in Schedule I of the Controlled Substances Act, the Drug Enforcement Administration wrote that "tianeptine has been shown to be pharmacologically similar to other mu-opioid agonists, including morphine (schedule II) and fentanyl (schedule II)," and noted that labels on products sold in the United States can list tianeptine content ranging from hundreds of milligrams up to more than 1,000 milligrams per dosage unit, far above the therapeutic dose used abroad. Case reports reviewed by the FDA describe consumers taking daily doses 1.3 to 250 times the labeled foreign dose, the equivalent of 50 milligrams up to 10,000 milligrams a day. The full proposed rule is published in the Federal Register through the Government Publishing Office.
Why poison control calls climbed
The trend line on tianeptine exposures has moved sharply upward. A report from the Centers for Disease Control and Prevention analyzing calls to the National Poison Data System found only 11 tianeptine-related calls nationwide between 2000 and 2013, followed by 207 calls between 2014 and 2017 alone, a pattern the agency flagged as an emerging public health risk. The CDC analysis is available directly at cdc.gov. That increase has continued. The DEA's proposed scheduling rule cites more recent poison center data showing tianeptine exposures reported to U.S. poison centers rose 1,400 percent from 2015 to 2023, including a 525 percent increase between 2018 and 2023 alone. Just over 40 percent of those exposures required medical admission, and nearly 23 percent required a critical care unit stay.
Clinical signs reported in these cases track closely with opioid toxicity: respiratory depression, sedation, constricted pupils, and in overdose cases, coma and death. Withdrawal from regular use produces its own recognizable pattern, with agitation, nausea, vomiting, tachycardia, hypertension, diarrhea, tremor, and sweating among the most commonly reported symptoms in poison center data. Naloxone has reversed respiratory depression in multiple documented cases, which is itself evidence of opioid receptor involvement in tianeptine toxicity.
Why standard panels miss it
Immunoassay screening cups work by using antibodies designed to bind to specific drug classes. The OPI strip is built to flag morphine and codeine metabolites. OXY targets oxycodone and oxymorphone. FYL is built specifically for fentanyl and norfentanyl. Tianeptine's molecule does not resemble any of those target compounds closely enough to trigger a cross-reaction, so a person under the influence of tianeptine, even at doses producing clear opioid-like impairment, will typically screen negative across every opioid panel on a standard cup.
This is not a secret to the people using the product. Federal reviewers noted that "tianeptine is not routinely included in toxicological analysis, and specialized testing may be required to positively identify this substance," and that this gap likely contributes to underreporting of harm. Some users specifically favor substances like tianeptine because they produce an opioid-like effect while evading routine drug screens, a pattern the DEA's own analysis flagged as a driver of the product's growing popularity in the current environment of shifting street drug supply.
What panels catch and miss
| Panel or test | What it targets | Detects tianeptine? |
|---|---|---|
| Standard OPI strip | Morphine, codeine metabolites | No |
| OXY strip | Oxycodone, oxymorphone | No |
| FYL strip | Fentanyl, norfentanyl | No |
| MTD strip | Methadone metabolite EDDP | No |
| BUP strip | Buprenorphine | No |
| Standard 5, 10, or 12-panel cup | NIDA-5 plus common add-ons | No |
| Send-out LC-MS/MS toxicology panel | Compound-specific mass spectrometry, ordered for tianeptine specifically | Yes, when the lab is instructed to look for it |
What specialized testing can do
Detecting tianeptine reliably requires liquid chromatography-tandem mass spectrometry, LC-MS/MS, run at a reference or forensic toxicology laboratory that has validated a method for the compound and its metabolites. This is not a test that shows up as an add-on strip on a point-of-care cup. It has to be specifically requested as a send-out, and the lab needs to know to look for tianeptine rather than running a generic opioid confirmation, because tianeptine will not trigger a presumptive positive that would normally prompt confirmation in the first place. Programs that suspect tianeptine use, based on clinical presentation, patient disclosure, or product found on a patient, should communicate that suspicion directly to the confirming laboratory rather than relying on a routine non-negative to trigger the right test. For background on how confirmation testing generally works once a screen flags a result, see what lab confirmation does after a non-negative screen.
State bans and the pending federal rule
Tianeptine is not currently a federally controlled substance, but that status is changing. In July 2026, the DEA proposed placing tianeptine in Schedule I of the Controlled Substances Act, citing its opioid-like abuse potential, lack of any FDA-approved medical use, and lack of accepted safety under medical supervision. That rule was still in the proposed stage as of this writing.
States have moved well ahead of federal action. According to the DEA's own review of state activity in its proposed rule, tianeptine has already been controlled or otherwise banned in Alabama, Arkansas, Florida, Georgia, Indiana, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Mississippi, Ohio, Oklahoma, Tennessee, and Virginia, with the earliest state action dating to 2018. Minnesota's statute, for example, lists tianeptine as a Schedule I controlled substance directly in state code, viewable through the Minnesota Office of the Revisor of Statutes. The DEA noted that even where states have scheduled the substance, bans have not stopped cross-state purchasing or online sales, which is part of why federal scheduling was proposed.
What treatment programs should do when tianeptine is suspected
A negative opioid panel does not rule out tianeptine, and clinical judgment has to fill that gap. Signs worth acting on include respiratory depression or sedation without a positive opioid screen, an opioid-like withdrawal pattern in a patient who denies opioid use, disclosure of Zaza, Tianaa, Neptune's Fix, or similar product use, and any response to naloxone in a patient who tested negative for opioids. When any of these appear, the practical steps are to treat the presentation clinically first, since naloxone response does not depend on a lab result, then send a specimen for LC-MS/MS confirmation with tianeptine specifically named as the target analyte, document the product name and packaging if available since labeling on these products is unreliable and varies by batch, and check current state law, since possession or sale may already carry criminal penalties in states that have scheduled the substance. Programs building out their standard panel selection to close known gaps like this one can review how broader panel options compare in 12 vs 14 vs 18 panel drug test cups, and can review the full range of cups, dip cards, and oral fluid options through American Screening Corp's drug testing collection.
Frequently asked questions
Will a standard drug test cup show a positive for tianeptine?
No. Standard immunoassay panels, including OPI, OXY, FYL, MTD, and BUP strips, are built around antibodies for specific opioid compounds that do not cross-react with tianeptine. A person actively using tianeptine will typically screen negative on every opioid panel on a routine cup.
What kind of test can actually detect tianeptine?
Liquid chromatography-tandem mass spectrometry, LC-MS/MS, performed at a laboratory that has validated a method for tianeptine and its metabolites. This has to be ordered as a specific send-out test rather than a routine confirmation, since a negative screen normally would not trigger any confirmation testing at all.
Is tianeptine actually an opioid?
It is not classified as an opioid chemically, but research shows it acts as an agonist at the mu-opioid receptor, the same receptor targeted by morphine and fentanyl. Federal reviewers have described its pharmacological effects, adverse event profile, and withdrawal pattern as similar to other mu-opioid agonists.
Is tianeptine legal to sell?
It depends on the state. At least fifteen states have already controlled or banned tianeptine sale, and the DEA has proposed placing it in Schedule I federally. Where no state or federal ban applies, it can currently be sold as an unregulated product, often labeled as a supplement.
What should a treatment program do if a client shows opioid-like symptoms but tests negative?
Treat the clinical presentation first, since sedation and respiratory depression need immediate attention regardless of screen results. Then send a specimen for targeted LC-MS/MS testing naming tianeptine specifically, and ask directly about use of gas station or smoke shop products sold as mood enhancers or energy supplements.
Related reading
This article is general information, not medical or legal advice. Testing protocols, panel selection, and state law on tianeptine vary and change, and programs should confirm current requirements with their laboratory and legal counsel before acting on a suspected case.
